Invictus MD (CNX:IMH) – Mr. Kveton is a highly effective, strategic and pragmatic international executive and investment professional, with broad experience operating in both Fortune 500 and start-up environments. He has a proven record in generating top-line growth by executing cross-border merger and acquisition deals and transformations to a high standard, and in developing new profit streams in regulated industries.
He is currently one of the founding partners of Logscale Venture Partners, a firm focused on early- and growth-stage companies in the health care space. Operating out of Switzerland, Mr. Kveton provides investors with early exposure to disruptive innovations/technologies in pharma, medtech, biotechnology and life science, and in the adjacent fields of personalized medicine, diagnostics and e-health. He has in-depth strategic and corporate development experience of the fast-moving consumer goods and has had extensive involvement with leading consultancy companies.
With over 20 years of deal-making experience, Mr. Kveton has worked for leading tobacco players. As vice-president, business development, at Japan Tobacco International (JTI) he led several M&A transactions valued at $1.5-million (U.S.), and was appointed by the chief executive officer to expand JTI’s presence in the United States and Latin America, with parallel responsibility for deal origination and execution in the area of emerging products. Formerly while at Philip Morris International, he led two major acquisitions (up to $1-billion (U.S.)), readied businesses in Poland, Hungary, Czech and Slovak Republics for European Union accession, and facilitated new market entries into Croatia and neighbouring countries. His multibillion-dollar private and public company deal sheet is global, spanning five continents.
A graduate of Queen’s University in Canada, and executive programs at U.C. Berkeley Haas School of Business and Harvard Business School, Mr. Kveton is an active angel investor and a true partner to entrepreneurs, bringing stewardship and management depth to their businesses.
“George is an outstanding addition to the board, bringing extensive global business development, finance and acquisition experience, and further enhancing our board,” said Dan Kriznic, chairman and chief executive officer. “His international network and reputation, along with his valuable knowledge and sound judgment, will serve the company and our shareholders well, as we continue on our journey of rapid growth, which includes expanding our production capacity and further establishing our leadership position as Canada’s cannabis company.”
“I am delighted to join Invictus MD and to become part of this truly dynamic team that will continue to provide leadership in the burgeoning cannabis sector,” said Mr. Kveton. “This company has captivated me in terms of its rapid growth, management and board strength, disciplined execution of its strategic plan, and vision for the future of the industry. I look forward to contributing to Invictus MD’s strategic decision making.”
About Invictus MD Strategies Corp.
Invictus MD Strategies is focused on three main verticals within the burgeoning Canadian cannabis sector: licensed producers under the cannabis for medical purposes regulations (ACMPR); fertilizer and nutrients through Future Harvest Development Ltd.; and cannabis data and delivery, with its wholly owned subsidiary Poda Technologies Ltd.
Click here to connect with Invictus MD (CNX:IMH) to receive an Investor Presentation.
Meanwhile, two longstanding cannabis partners ended their relationship.
Trulieve to donate $20,000 in scholarship funding and $15,000 to support leadership development
Trulieve Cannabis Corp . (CSE: TRUL) (OTC: TCNNF), a leading and top-performing cannabis company in the United States today announced a new partnership with the Thurgood Marshall College Fund (TMCF), the nation’s largest organization exclusively representing the Black College Community. Trulieve will donate $20,000 to help fund several college scholarships awarded to students who are attending one of the organization’s member-schools as part of Trulieve’s diversity, equity, and inclusion initiatives. The $15,000 in talent funding is earmarked to support TMCF’s internship program, reaching a diverse talent pool of students and alumni from their 47 member-schools to provide immersive experiences at Trulieve.
The new dispensary expands patient access to Florida’s largest inventory of medical cannabis products
Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 80th nationwide. The new location marks the Company’s first in Tamarac and third in Broward County expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.
Revive Therapeutics Provides Update on FDA Phase 3 Clinical Trial for Bucillamine in COVID-19 with Planned Completion and Emergency Use Authorization Request
Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild to moderate COVID-19.
With its recent $23 million dollar financing, the Company plans to aggressively expand from 14 clinical sites to up to 50 clinical sites to meet the next enrollment goals for the Study in Q2-2020. The Study is a randomized, double-blinded, placebo-controlled trial and the safety and efficacy data analyzed at each interim analysis timepoint of 210, 400, 600 and 800 completed patients are only made available to the Independent Data and Safety Monitoring Board (“DSMB”) for review and recommendations on continuation, stopping or changes to the conduct of the Study. In the event of any serious safety concerns, the DSMB would be notified to determine any risks and provide its recommendations. To date, in this initial 210 interim point there have been no serious safety concerns that required the DSMB to be notified.
HempFusion Wellness Inc. (TSX:CBD.U) (OTCQX:CBDHF) (FWB:8OO) (“HempFusion” or the “Company”), a leading health and wellness CBD company utilizing the power of whole-food hemp nutrition, is pleased to announce that its common shares have been approved for DTC full-service eligibility in the United States by the Depository Trust Company (“DTC”) and can now be both traded and serviced through DTC’s electronic book-entry system.
DTC is a subsidiary of the Depository Trust & Clearing Corp. (“DTCC”) that provides clearing and settlement services for the financial markets and settles the majority of securities transactions in the United States. This electronic method of clearing securities speeds up the receipt of stock and cash and thus accelerates the settlement process for investors and brokers, enabling the stock to be traded over a much wider selection of brokerage firms.